Free DePinho resigns as MD Anderson president, acknowledges shortcomings as administrator March 09, 2017Vol.43 No.10By Paul Goldberg
Drugs & TargetsFree FDA approves Xermelo as first and only treatment for carcinoid syndrome diarrhea March 03, 2017Vol.43 No.09
Drugs & TargetsFree FDA Accepts avelumab BLA for Priority Review for urothelial carcinoma March 03, 2017Vol.43 No.09
Drugs & TargetsFree BMS expands International Immuno-Oncology Network with addition of Columbia and MacCallum Cancer Centre March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, BMS collaborate on late-stage combination trial in first-line RCC March 03, 2017Vol.43 No.09
Drugs & TargetsFree Exelixis, Roche to evaluate cabozantinib and atezolizumab in solid tumors March 03, 2017Vol.43 No.09
Drugs & TargetsFree Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy March 03, 2017Vol.43 No.09
FreeIn Brief Karmanos, Wayne State receive grant to conduct nation’s largest study of factors affecting African Americans with cancer March 03, 2017Vol.43 No.09
FreeIn Brief Feldman named chief of breast surgery & surgical oncology, director of breast cancer services at Montefiore and Einstein March 03, 2017Vol.43 No.09
FreeIn Brief Michael Rosen named chief communications officer at Pancreatic Cancer Action Network March 03, 2017Vol.43 No.09
